TITLE

VICAL LICENCEE ANGES MG FILES NDA IN JAPAN FOR COLLATEGENE

PUB. DATE
May 2008
SOURCE
Worldwide Biotech;May2008, Vol. 20 Issue 5, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labor and Welfare by AnGes MG Inc. for its angiogenesis product candidate, Collategene. The product is for treatment of critical limb ischemia, which uses Vical Inc. technology to deliver a gene encoding hepatocyte growth factor (HGF). HGF is a human protein that causes growth of blood vessels in areas of restricted blood flow.
ACCESSION #
31784380

 

Related Articles

  • Strategies in Infrapopliteal Intervention: Improving Outcomes in Challenging Patients. Nair, Vinod; Chaisson, Gary; Abben, Richard // Journal of Interventional Cardiology;Feb2009, Vol. 22 Issue 1, p27 

    The article discusses the safe and effective treatment in patients with infrapopliteal disease and critical limb ischemia (CLI) resistant. It states that percutaneous intervention is performed in patients with CLI in order to avoid major amputation and sustain viability of the limb. It also lays...

  • Circulator boot therapy alters the natural history of ischemic limb ulceration. Vella, A.; Carlson, L.A.; Blier, B.; Felty, C.; Rooke, T.W.; Kuiper, J.D. // Vascular Medicine;2000, Vol. 5 Issue 1, p21 

    Despite numerous advances in interventional radiology and vascular surgery, the clinician continues to be confronted with inoperable vascular disease. Previous studies have shown that ulceration associated with a transcutaneous oxygen pressure (tcPO2)of ,20 mmHg is refractory to all attempts at...

  • FDA, Vical Licensee Agree on Phase III Design for Collategene. Hollingsworth, Catherine // BioWorld Today;1/13/2010, Vol. 21 Issue 8, p4 

    The article reports on an agreement reached by AnGes MG Inc. with the U.S. Food and Drug Administration (FDA) concerning the design of a Phase III trial of Collategene. It is noted that Collategene has the potential to treat patients with peripheral arterial disease (PAD). The underlying...

  • Vical Prices $33.8M Offering on Heels of Partner Setbacks. Morrison, Trista // BioWorld Today;9/27/2010, Vol. 21 Issue 186, p1 

    The article reports on the plan of Vical Inc. to raise 33.8 million U.S. dollars through a public offering following the announcement of setbacks by its partners. Sanofi-Aventis Group SA has confirmed the failure of a Phase III trial for the drug Temusi, while AnGes MG Inc. decided to abandon a...

  • Lymphedema: classification, diagnosis and therapy. Szuba, A.; Rockson, S.G. // Vascular Medicine;1998, Vol. 3 Issue 2, p145 

    This review presents the diagnostic features, the pathophysiology and the available therapies for lymphedema. This disease is often able to be diagnosed by its characteristic cliniccal presentation, yet, in some cases, ancillary tests might be necessary to establish the diagnosis, particularly...

  • Changes in Serum Human Hepatocyte Growth Factor Levels after Transcatheter Arterial Embolization and Partial Hepatectomy. Kaneko, Akira; Hayashi, Norio; Tanaka, Yuji; Ito, Toshifumi; Kasahara, Akinori; Kubo, Mitsuhiko; Mukuda, Tomoyuki; Fusamoto, Hideyuki; Kamada, Takenobu // American Journal of Gastroenterology;Aug1992, Vol. 87 Issue 8, p1014 

    We examined the changes in serum human hepatocyte growth factor (hHGF), also called "scatter factor," levels after transcatheter arterial embolization (TAE) and partial hepatectomy (PH) in patients with hepatocellular carcinoma and metastatic liver tumor. In most cases, the serum hHGF levels...

  • Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Ueki, Takahiro; Kaneda, Yasufumi; Tsutsui, Hiroko; Nakanishi, Kenji; Sawa, Yoshiki; Morishita, Ryuichi; Matsumoto, Kunio; Nakamura, Toshikazu; Takahashi, Hiroshi; Okamoto, Eizo; Fujimoto, Jiro // Nature Medicine;Feb1999, Vol. 5 Issue 2, p226 

    Liver cirrhosis is the irreversible end result of fibrous scarring and hepatocellular regeneration, characterized by diffuse disorganization of the normal hepatic structure of regenerative nodules and fibrotic tissue. It is associated with prominent morbidity and mortality, and is induced by...

  • Nonviral gene transfer of human hepatocyte growth factor improves streptozotocin-induced diabetic neuropathy in rats. Kato, Naoki; Nemoto, Koichi; Nakanishi, Kuniaki; Morishita, Ryuichi; Kaneda, Yasufumi; Uenoyama, Maki; Ikeda, Tomosumi; Fujikawa, Kyosuke // Diabetes;Mar2005, Vol. 54 Issue 3, p846 

    Peripheral neuropathy is common and ultimately accounts for significant morbidity in diabetes. Recently, several neurotrophic factors have been used to prevent progression of diabetic neuropathy. In this study, we gave repeated intramuscular injections of the human hepatocyte growth factor (HGF)...

  • Research & Markets: Peripheral Artery Disease (PAD) Therapeutics -- Pipeline Assessment and Market Forecasts to 2018 -- Market to reach $7422.3m by 2018.  // Biomedical Market Newsletter;12/21/2011, Vol. 21, p1 

    The article offers information related to an announcement made by Research & Markets Ltd. regarding addition of a new report titled "Peripheral Artery Disease (PAD) Therapeutics -- Pipeline Assessment and Market Forecasts to 2018," to their offering. As per the report, the current PAD...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics